BO-112 Plus Pembrolizumab for Patients With Anti–PD-1–Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203
Iván Márquez‐Rodas(Hospital General Universitario Gregorio Marañón), Stéphane Dalle(Mount Sinai Hospital), S. Prey(Centre Hospitalier Universitaire de Bordeaux), Sonia Rodrı́guez, Luis de la Cruz‐Merino, Miguel F. Sanmamed(Clinica Universidad de Navarra), Ignacio Melero(Universidad de Navarra), Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), Marya Chaney(Merck & Co., Inc., Rahway, NJ, USA (United States)), Elisa Funck‐Brentano(Institut Mondor de Recherche Biomédicale), Henri Montaudié(Hôpital l'Archet), Juan F. Rodríguez-Moreno(Hospital Universitario HM Sanchinarro), Marisol Quintero(Highlight Therapeutics (Spain)), Zuzana Jirakova Trnkova(Highlight Therapeutics (Spain)), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), M.P. Lopez Criado(MD Anderson Cancer Center Madrid), María González‐Cao(Instituto Oncológico Dr. Rosell), J. Charles(Apple (Israel)), Ma Carmen Álamo de la Gala(Hospital Universitario Virgen Macarena), Caroline Robert(Centre National de la Recherche Scientifique), Pablo Cerezuela(Instituto Murciano de Investigación Biosanitaria), Enrique de Miguel(Universidad de Huelva), Alfonso Berrocal, Jose Antonio Avilés‐Izquierdo(Hospital General Universitario Gregorio Marañón), Ruth Román, Eduardo Castañón Álvarez(Clinica Universidad de Navarra), Beatriz García‐Peláez, Sonia Maciá(Highlight Therapeutics (Spain)), Ana Arance(Hospital Clínic de Barcelona)
Cited by 7
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.8k